HypertensionREMAP-BPNCT07623291
Monitoring Blood Pressure at Home and Pharmacy Telehealth
A study testing Remote Blood Pressure Monitoring + Telehealth in people with Hypertension and Blood Pressure, run by University of Alabama at Birmingham at 1 site in United States.
Trial summary
The overall goal of this project is to determine if measuring blood pressure at home and staying in contact with a team of pharmacists and physicians to manage participants' blood pressure is useful. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Hypertension, Blood Pressure
- What is being tested?
- Remote Blood Pressure Monitoring + Telehealth
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 420 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Apr 2027to Jan 2031
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age ≥18 years
- Ability to speak English
- Seen at UAB's or TGH's Emergency Department-Transitional Care Clinic
- Blood pressure at Emergency Department-Transitional Care Clinic: Systolic BP ≥ 130 mmHg or Diastolic BP ≥ 80 mmHg
- Have a cellphone with video capability
Who cannot join
- Systolic BP ≥ 160 mmHg or Diastolic BP ≥ 100 mmHg (i.e. severe range hypertension (HTN) by the 2025 American College of Cardiology/American Heart Association BP guidelines) as they typically are referred to immediate treatment intensification. Since the prevalence of severe HTN is low (i.e.<5%) in the US population, exclusion of these individuals will have only a small effect on the study.)
- Lack of willingness or inability to provide written informed consent
- Individuals who work overnight or second shift
- History of known major arrhythmias
- Currently pregnant or breastfeeding
- Arm circumference >50 cm. *The upper limit for the largest BP cuff for oscillometric BP devices is typically 50-52 cm; data from the National Health and Nutrition Examination Survey, 2011-2016 indicated that <1% of US adults have an arm circumference >50 cm, so this will have minimal effect on our study.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site
University of Alabama at Birmingham
Birmingham, Alabama, 35233
Tammi Thomas, 205-934-7839, tammithomas@uabmc.edu
Bernadette Johnson, 205-934-7329, bajohnson@uabmc.edu
About this study
Official title: REmote Blood Pressure Monitoring and Pharmacist-Led Telehealth Program in an Emergency Department Transitional Care Clinic
The overall goal of this project is to determine if measuring blood pressure at home and staying in contact with a team of pharmacists and physicians to manage participants' blood pressure is useful. The study will enroll 400 participants who are seen at the University of Alabama at Birmingham Emergency Department - Transitional Care Clinic and Tampa General Hospital -Transitional Care Clinic. Half of the participants (200 patients) will be asked to measure blood pressure at home, and half of the participants (200 patients) will continue to receive usual care. Participants who measure blood pressure at home will also meet with a pharmacist weekly over the phone to discuss blood pressure readings and have blood pressure medications prescribed if needed. This program will last 6 months.
Read the detailed description
For all participants:
- Participants will receive information on the importance of measuring blood pressure and ways to improve blood pressure.
- Participants will complete questionnaires describing current socioeconomic position, medical history and healthcare needs.
- Participants will come in for three research clinic visits to get blood pressure measured 3 months after enrollment in this study, and 6 months after enrollment in this study.
For participants asked to measure blood pressure at home:
- Measure blood pressure twice a day at home, following the instructions provided. The study will provide participants with the device and send text message reminders each week day. Participants will return the device at study visit 3 months from now.
- Following the instructions provided, participants will talk to a pharmacist over the phone weekly to discuss blood pressure and medications. All medication changes will be discussed with a collaborating physician.
- Participants will complete questionnaires and interviews on satisfaction with the program.
- Conditions
- Hypertension, Blood Pressure
- Being tested
- Remote Blood Pressure Monitoring + Telehealth
- Keywords
- Cardiovascular Diseases, Delivery of Health Care, Patient Care Management, Health Services Administration, Telemedicine, Vascular Diseases
- Medical subject headings
- Hypertension, Cardiovascular Diseases, Vascular Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Remote Blood Pressure Monitoring + TelehealthBehavioural
Participants will undergo remote blood pressure monitoring and pharmacist led telehealth intervention for blood pressure management
| Study group | Role | What they receive |
|---|---|---|
| Remote Blood Pressure Monitoring + Telehealth | Active comparator | Participants will undergo remote blood pressure monitoring and pharmacist led telehealth intervention for blood pressure management Receives: Behavioral: Remote Blood Pressure Monitoring + Telehealth |
| Usual Care | No intervention | Participants receive usual care from providers to manage blood pressure |
What is being measured
The primary outcome is the main question the study is designed to answer.
Total Number of Enrolled Participants with Blood Pressure Control
The number of enrolled participants with blood pressure control
Measured: 12 weeks (3 months) from randomization
Secondary outcomes (1)
Number of Participants in the Intervention with Patient-Reported Outcomes
The number of participants with completed qualitative interviews and surveys regarding intervention adherence and satisfaction.
The survey will assess intervention adherence and satisfaction using the following scales: Acceptability of Intervention Measure (AIM), Intervention Appropriateness Measure (IAM), and the Feasibility of Intervention Measure (FIM).
The AIM is a 4-item scale where the min. value per item is 1 and the max. value per item is 5. A higher total score indicates better acceptability while the lower total score indicates worse acceptability.
The IAM is a 4-item scale where the min. value per item is 1 and the max. value per item is 5. A higher total score indicates better appropriateness while the lower total score indicates worse appropriateness.
The FIM is a 4-item scale where the min. value per item is 1 and the max. value per item is 5. A higher total score indicates better feasibility while the lower total score indicates worse feasibility.
Measured: 24 weeks (6 months) from randomization
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Jun 2026
- Study start1 Apr 2027 (estimated)
- Primary completionJan 2031 (estimated)
- Study completionJan 2031 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HypertensionStudies of the same condition, open and under way.
- More trials run by University of Alabama at BirminghamThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 420 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Alabama at Birmingham
- Sponsor type
- University, hospital or other
- Collaborators
- National Heart, Lung, and Blood Institute (NHLBI)
- Responsible party
- Principal investigator, Lama Ghazi, University of Alabama at Birmingham
- Investigators
- Lama Ghazi, MD, PhD, Principal investigator, University of Alabama at Birmingham
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07623291
- Sponsor's protocol ID
- IRB-300016615
- Other IDs
- National Heart, Lung, & Blood
- Acronym
- REMAP-BP
- Status last verified
- May 2026
- First submitted
- 28 May 2026
- Last updated
- 15 Jun 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: While the investigators do not anticipate generating research tools, the investigators are committed to adhering to the National Institutes of Health (NIH) Research Tools Policy to ensure that any resources developed under this award are readily available to qualified researchers. If an NIH-defined research tool is developed, the investigators will collaborate with University of Alabama at Birmingham Commercialization and Licensing Office and all participating institutions to define ownership, protect intellectual property, and establish a dissemination strategy that ensures appropriate access and compliance with NIH guidelines.
Study at a glance
From the registry record, last updated by the sponsor on 15 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- REmote Blood Pressure Monitoring and Pharmacist-Led Telehealth Program in an Emergency Department Transitional Care Clinic
- ClinicalTrials.gov ID
- NCT07623291
- Acronym / sponsor ID
- REMAP-BP / IRB-300016615
- Conditions
- Hypertension, Blood Pressure
- Keywords
- Cardiovascular Diseases, Delivery of Health Care, Patient Care Management, Health Services Administration, Telemedicine, Vascular Diseases
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 420 participants (estimated)
- Lead sponsor
- University of Alabama at BirminghamUniversity, hospital or other
- Collaborators
- National Heart, Lung, and Blood Institute (NHLBI)
- Study start
- 1 Apr 2027 (estimated)
- Primary completion
- Jan 2031 (estimated)
- Study completion
- Jan 2031 (estimated)
- First posted
- 3 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The overall goal of this project is to determine if measuring blood pressure at home and staying in contact with a team of pharmacists and physicians to manage participants' blood pressure is useful. The study will enroll 400 participants who are seen at the University of Alabama at Birmingham Emergency Department - Transitional Care Clinic and Tampa General Hospital -Transitional Care Clinic. Half of the participants (200 patients) will be asked to measure blood pressure at home, and half of the participants (200 patients) will continue to receive usual care. Participants who measure blood pressure at home will also meet with a pharmacist weekly over the phone to discuss blood pressure readings and have blood pressure medications prescribed if needed. This program will last 6 months.
Detailed description
For all participants:
- Participants will receive information on the importance of measuring blood pressure and ways to improve blood pressure.
- Participants will complete questionnaires describing current socioeconomic position, medical history and healthcare needs.
- Participants will come in for three research clinic visits to get blood pressure measured 3 months after enrollment in this study, and 6 months after enrollment in this study.
For participants asked to measure blood pressure at home:
- Measure blood pressure twice a day at home, following the instructions provided. The study will provide participants with the device and send text message reminders each week day. Participants will return the device at study visit 3 months from now.
- Following the instructions provided, participants will talk to a pharmacist over the phone weekly to discuss blood pressure and medications. All medication changes will be discussed with a collaborating physician.
- Participants will complete questionnaires and interviews on satisfaction with the program.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Remote Blood Pressure Monitoring + Telehealth | Active comparator | Behavioral: Remote Blood Pressure Monitoring + TelehealthParticipants will undergo remote blood pressure monitoring and pharmacist led telehealth intervention for blood pressure management |
| Usual Care | No intervention | –Participants receive usual care from providers to manage blood pressure |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Age ≥18 years
- Ability to speak English
- Seen at UAB's or TGH's Emergency Department-Transitional Care Clinic
- Blood pressure at Emergency Department-Transitional Care Clinic: Systolic BP ≥ 130 mmHg or Diastolic BP ≥ 80 mmHg
- Have a cellphone with video capability
Key exclusion criteria (6 listed)
- Systolic BP ≥ 160 mmHg or Diastolic BP ≥ 100 mmHg (i.e. severe range hypertension (HTN) by the 2025 American College of Cardiology/American Heart Association BP guidelines) as they typically are referred to immediate treatment intensification. Since the prevalence of severe HTN is low (i.e.<5%) in the US population, exclusion of these individuals will have only a small effect on the study.)
- Lack of willingness or inability to provide written informed consent
- Individuals who work overnight or second shift
- History of known major arrhythmias
- Currently pregnant or breastfeeding
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Remote Blood Pressure Monitoring + TelehealthParticipants will undergo remote blood pressure monitoring and pharmacist led telehealth intervention for blood pressure management | Behavioural | Remote Blood Pressure Monitoring + Telehealth |
Primary outcome
Total Number of Enrolled Participants with Blood Pressure Control
Time frame: 12 weeks (3 months) from randomization
The number of enrolled participants with blood pressure control
1 secondary outcome
Number of Participants in the Intervention with Patient-Reported Outcomes
Time frame: 24 weeks (6 months) from randomization
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Jun 2026.
- Individual participant dataSharing planned: No. While the investigators do not anticipate generating research tools, the investigators are committed to adhering to the National Institutes of Health (NIH) Research Tools Policy to ensure that any resources developed under this award are readily available to qualified researchers. If an NIH-defined research tool is developed, the investigators will collaborate with University of Alabama at Birmingham Commercialization and Licensing Office and all participating institutions to define ownership, protect intellectual property, and establish a dissemination strategy that ensures appropriate access and compliance with NIH guidelines.
Related trials for Hypertension
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Recruiting
Trial Phase: Syndemic Adapted Medly Uganda
Mental Health
Not yet recruitingPhase 2/3
An Open-Label Extension Study to Evaluate Inhaled Treprostinil SMI in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
Enrolling by invitation
Testing Implementation Strategies to Support Clinic Fidelity to an Outpatient Hypertension Bundle
Pregnancy Related, Hypertension
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Lama Ghazi, MD, PhD principal investigator
University of Alabama at Birmingham
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Remote Blood Pressure Monitoring + Telehealth in people with Hypertension and Blood Pressure, run by University of Alabama at Birmingham at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 15 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Tammi Thomas (205-934-7839, tammithomas@uabmc.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Total Number of Enrolled Participants with Blood Pressure Control (time frame: 12 weeks (3 months) from randomization). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Jun 2026.